Back to top
more

SiBone (SIBN)

(Delayed Data from NSDQ)

$16.55 USD

16.55
720,502

+1.65 (11.07%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $16.52 -0.03 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Edwards' (EW) Innovation Aids Growth, Critical Care Flourishes

by Zacks Equity Research

Edwards' (EW) Surgical Structural Heart sales growth is lifted by the increased adoption of its premium products across all regions.

Sensus Healthcare (SRTS) Expands Global Base With New Pact

by Zacks Equity Research

The agreement includes the distribution of Sensus Healthcare's (SRTS) SRT-100, SRT-100+ and SR-100 Vision systems, specifically designed for the treatment of non-melanoma skin cancer and keloids.

Bruker (BRKR) Showcases UK Science Investments at EUROMAR 2023

by Zacks Equity Research

Bruker (BRKR) begins advanced life-science and green-tech research in the United Kingdom.

Quanterix (QTRX) Advances in Alzheimer's Diagnosis With LucentAD

by Zacks Equity Research

Quanterix (QTRX) LucentAD biomarker blood test aims to assist healthcare providers in evaluating patients who show cognitive symptoms consistent with the early signs of AD.

Thermo Fisher (TMO) Announces the Acquisition of CorEvitas

by Zacks Equity Research

Thermo Fisher's (TMO) acquisition of CorEvitas is likely to strengthen its value proposition.

ResMed (RMD) Expands Solutions Portfolio With Somnoware Buyout

by Zacks Equity Research

ResMed (RMD) announces the acquisition of the Somnoware diagnostic management platform.

Best Momentum Stocks to Buy for July 6th

by Zacks Equity Research

NCR, GBX and SIBN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 6, 2023.

Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker

by Zacks Equity Research

Abbott (ABT) receives FDA approval for the AVEIR DR leadless pacemaker system, featuring the proprietary i2i technology.

New Strong Buy Stocks for July 6th

by Zacks Equity Research

GBX, GFF, AVDX, NCR and SIBN have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2023.

Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement

by Zacks Equity Research

Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.

Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays

by Zacks Equity Research

Intensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships.

Penumbra (PEN) Hits 52-Week High: What's Driving the Rise?

by Zacks Equity Research

Penumbra (PEN) outperforms the industry and the S&P 500, backed by investors' optimism about the recently released first-quarter 2023 results.

Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing

by Zacks Equity Research

Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.

Si-Bone (SIBN) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Si-Bone (SIBN) delivered earnings and revenue surprises of 21.95% and 12.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in TransMedics (TMDX): Can Its 12.3% Jump Turn into More Strength?

by Zacks Equity Research

TransMedics (TMDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Si-Bone (SIBN) delivered earnings and revenue surprises of 23.81% and 0.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Acadia (ACHC) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Acadia Healthcare's (ACHC) fourth-quarter results are likely to reflect an increase in patient days and admissions.

What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong performance in the Technologies & Equipment business.

Universal Health (UHS) to Post Q4 Earnings: What to Expect

by Zacks Equity Research

Universal Health's (UHS) fourth-quarter results are likely to reflect an increase in same facility adjusted admissions in acute care hospitals.

Select Medical (SEM) to Post Q4 Earnings: What to Expect

by Zacks Equity Research

Select Medical's (SEM) fourth-quarter results are likely to reflect improved figures in the Rehabilitation Hospital business.

Avanos Medical (AVNS) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of 25% and 1.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Teladoc's (TDOC) Q4 Earnings Beat on Growing Visits?

by Zacks Equity Research

The fourth-quarter results of Teladoc Health (TDOC) are likely to reflect a rise in visits and memberships.

Pediatrix Medical (MD) to Post Q4 Earnings: What to Expect

by Zacks Equity Research

Pediatrix Medical's (MD) fourth-quarter results are likely to reflect higher operating expenses and patient volume growth.